Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Memorial Sloan Kettering Cancer Center · Institut Gustave Roussy · +9 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
744
total citations
- FWCI
- 66.60
- Percentile
- 100%
- References
- 26
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Axitinib
- Medicine
- Sorafenib
- Renal cell carcinoma
- Internal medicine
- Clinical endpoint
- Hazard ratio
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.